Today Stories

Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data Global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine Aim is for global supply through the COVAX facility in the first half of 2022, subject to data and regulatory review SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s pandemic adjuvant following positive interim Phase 1/2 results. The randomised, active-controlled global trial will enrol around 4,000 participants from a range of countries and will aim to evaluate GBP510’s safety and immunogenicity compared to an active comparator - the AstraZeneca/Oxford University COVID-19 vaccin…

Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology. Lycia uses its next-generation degradation approach to target the untapped extracellular proteome, including cell surface receptors and secreted proteins. The LYTAC platform may enable the development of several therapeutic modalities, including antibodies and small molecules, with the potential to inhibit many targets previously considered intractable across a spectrum of therapeutic areas and diseases. Under the terms of the agreement, the companies will utilize Lyci…

Purpose-built facility to enable precision medicine for better patient outcomes Cerba Research, a leading global clinical trial laboratory services organization owned by Cerba HealthCare, announced today that they have joined forces with ACT Genomics under a joint venture model to create a purpose-built lab facility in Taiwan covering the Asia Pacific region.   This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.  The expansion includes investments in a new facility in Taipei (Taiwan)…

Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives Pfizer Inc. (NYSE: PFE) and Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.…

NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, today announced further equity investment of £490k from Parkinson’s UK, to support the development of disease modifying drugs for the treatment of Parkinson’s. Following positive progress, this is the third investment Parkinson’s UK has made into NRG Therapeutics, bringing the total amount to £2.5m. The funding comes via the charity’s drug development arm, the Parkinson’s Virtual Biotech, a programme which is plugging the funding gap to fast-track the projects with the greatest scientific potential to transform the lives of people with Parkinson’s. This new funding will be used to progress the company’s lead drug candidates toward preclinical development candidate nomination. …

New Brunswick, N.J. (August 19, 2021) – Johnson & Johnson (NYSE: JNJ) today announced that Mr. Alex Gorsky, currently Chairman and Chief Executive Officer, will serve as Executive Chairman of Johnson & Johnson and transition the Chief Executive Officer role to Mr. Joaquin Duato, currently Vice Chairman of the Company’s Executive Committee, effective January 3, 2022. Following the transition of the Chief Executive Officer role, Mr. Duato will also be appointed as a member of the Company’s Board of Directors. “It has been an honor and privilege to lead this company as Chairman and CEO for nearly a decade, and I am pleased to serve as Executive Chairman to help oversee Johnson & Johnson’s ongoing progress improving the health of people and communities everywhere,” said Mr. Gorsky.…

The INHANCE™ Shoulder System empowers surgeons to treat a broad range of cases with a streamlined, comprehensive implant offering that features common instrumentation and unique interoperative flexibility Designed for hospitals as well as outpatient and ASC settings where economic value and operational efficiency are critical considerations Today, The Johnson & Johnson Medical Devices Companies* announced that DePuy Synthes, The Orthopaedics Company of Johnson & Johnson,** introduces the INHANCE™ Shoulder System, a first-to-market, fully integrated shoulder arthroplasty system. The system is designed with an intuitive stemless-first surgical approach that aligns with how surgeons approach patient care. The INHANCE Shoulder System is the first shoulder system to offer surgeons t…

Melbourne (Australia) – 18 August 2021. Telix announces pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany. Telix today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany (Merck), to conduct combination studies with one of Merck’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix’s TLX591 (177Lu-rosopatamab) and TLX250 (177Lu-girentuximab) molecularly targeted radiation (MTR) therapeutic programs. This clinical collaboration builds on the success of a strategic research collaboration agreement between Telix and Merck announced in August 2019. TLX591 and TLX250 are late-stage products in development for prostate and renal cancer therapy, respectively. Under t…

Thermo Fisher Scientific, the world leader in serving science, and ChromSword, a provider of innovative software products, have collaborated to launch an automated high performance liquid chromatography (HPLC) and ultra-high performance liquid chromatography (UHPLC) method development system that enables chromatographers to deliver robust and validated methods in less time and with higher confidence. The new Thermo Scientific Vanquish Method Development HPLC and UHPLC system provides an integrated, network-deployable solution for automated method development and validation for diode-array, charged aerosol and mass spectrometric detection. Built for ease-of-use and speed, the system strategically combines the leading Vanquish HPLC and UHPLC systems and the Thermo Scientific Chromeleon Chrom…

Variants studied included Alpha, Beta, Gamma, Delta, Epsilon and Iota Majority of participants who received primary series maintain detectable binding and functional antibodies against variants for 6 months Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the publication of new data on the durability of the Moderna COVID-19 vaccine in generating neutralizing antibodies against variants of concern. The manuscript was published in Science. According to the paper, the majority of individuals vaccinated with the Moderna COVID-19 vaccine maintained both binding and functional antibodies against SARS-CoV-2 variants for six months after the second dose. “We are pleased with these new data showing that people vaccinat…

Medicines Discovery Catapult (MDC) and We Share Ventures have embarked on a joint venture, piloting an innovative funding model aimed at opening new funding opportunities for early-stage medicines discovery. For too long, accessing catalytic funding has been a challenge for medicines discovery start-ups focused on areas of clinical unmet need. This impact-driven revolving funding model is the first of its kind in the sector and has the potential to create and sustain funding opportunities for medicines discovery start-ups focused on patient impact. The pilot brings together We Share’s innovative impact-driven revolving funding model with MDC Syndicate’s programme, enabling promising start-ups in the medicine discovery space access to long-term capital in the early phases of their growth. T…

Manufacturing facility to provide access to domestically manufactured vaccines against respiratory viruses Collaboration will support Canada with direct access to rapid pandemic response capabilities First instance of sustainable national business model that Company expects to apply to other geographies Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a Memorandum of Understanding (MoU) with the government of Canada to build a state-of-the-art messenger RNA (mRNA) vaccine manufacturing facility in Canada including access to Moderna’s mRNA development engine. The goals of this MoU are to build the foundation to support Canada with direct access to rapid pandemic response capabilities and to provide access to M…

Vancouver, Canada. August 9, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen’s lead compound, NVG-291, in validated animal models of Alzheimer’s disease. “We are very happy to be collaborating with Massachusetts General Hospital and Dr. Kastanenka to study the mechanism of our technology in an Alzheimer’s disease model,” stated Dr. Daniel Mikol, NervGen’s Chief Medical Officer. “As the original and largest teaching hospital for Harvard University, and one of the largest funded…

– Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio – – Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, together with additional tiered royalties; HUTCHMED to receive development and commercial rights to TAZVERIK® in Greater China – – HUTCHMED to host a webcast and call on Monday, August 9, at 9:30 a.m. EDT / 2:30 p.m. BST / 9:30 p.m. HKT – see www.hutch-med.com/event for details – Hong Kong, Shanghai, Florham Park, N.J. and Cambridge, Mass—Monday, August 9, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Epizyme, Inc. (“Epizyme”) (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company dev…

Galt Pharmaceuticals®, a pharmaceutical company committed to enhancing the quality of life of patients with products that meet unmet clinical needs, has introduced a 4-day work week for its employees. In a LinkedIn post, CEO and Co-Founder Barry Patel said, “We are not big pharma and are actually looking to disrupt the inefficient big pharma model. We know we can’t always offer the big pharma perks, but we can offer work-life balance and a family-first culture.” About Galt Pharmaceuticals® Galt Pharmaceuticals® has found a better way to enhance the quality of life of patients with products that answer unmet clinical needs, while creating life-changing opportunities for entrepreneurs, our employees and the individuals within the communities we serve. Galt is the first and only company to cr…

- Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence - The new intuitive interface provides step-by-step guidance to enhance ease of use - When combined with Abbott's Dragonfly OpStar™ imaging catheter and PressureWire X™, the platform provides physicians with a comprehensive set of tools to provide better patient care Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. This innovative imaging software combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary blood flow…

Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas Fast tracks establishment of Sanofi’s recently announced mRNA Center of Excellence Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology PARIS and LEXINGTON, Mass – August 3, 2021 – As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully dilute…

BioMed X Institute to start two new research programs in the field of autoimmune diseases and drug delivery New research groups in Heidelberg to examine protective tissue factors in autoimmune diseases and the translocation of complex macromolecules across the intestinal epithelial barrier Heidelberg, 02.08.2021. German independent research institute BioMed X announces today the start of two new research projects with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The start of these projects represents a major milestone in the strategic partners’ successful collaboration and addresses two challenging new research areas. Both collaborations were facilitated by Johnson & Johnson Innovation. The new research group PTA (‘Pro…

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses. Through the multi-year collaboration, Kumquat will utilize its small molecule immuno-oncology (IO) platform to discover novel clinical candidates and Lilly has the option to select a certain number of drug candidates for further development and commercialization worldwide, excluding Greater China. Kumquat has retained development and commercialization rights in Greater China for each of the drug candidates selected by Lilly, subject to Lilly's option to co-commercialize in Greater China. Ad…

Collaboration seeks to obtain direct insights from patients to improve clinical trial accessibility, drive efficiency  Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced an innovative partnership with Cancer Hospital Chinese Academy of Medical Sciences (CHCAMS) to develop patient-centric protocol designs and methodologies for decentralized clinical trials in China. The collaboration will also include quantitative research to improve the clinical trial experience of oncology patients. “We are honored to be partnering with CHCAMS,” said Vicky Hsu, Corporate Vice President, Greater China Region Head and Head of Asia/Pacific Biotech Operations for Parexel. “The Cancer Hospital…